These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 26633185)

  • 1. Serum levels of granzyme B decrease in patients with rheumatoid arthritis responding to abatacept.
    Colombo E; Scarsi M; Piantoni S; Tincani A; Airò P
    Clin Exp Rheumatol; 2016; 34(1):37-41. PubMed ID: 26633185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced T-cell repertoire restrictions in abatacept-treated rheumatoid arthritis patients.
    Imberti L; Scarsi M; Zanotti C; Chiarini M; Bertoli D; Tincani A; Airò P
    J Transl Med; 2015 Jan; 13():12. PubMed ID: 25592982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased circulating CD28-negative T cells in patients with rheumatoid arthritis treated with abatacept are correlated with clinical response.
    Scarsi M; Ziglioli T; Airò P
    J Rheumatol; 2010 May; 37(5):911-6. PubMed ID: 20231200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction of peripheral blood T cells producing IFN-γ and IL-17 after therapy with abatacept for rheumatoid arthritis.
    Scarsi M; Zanotti C; Chiarini M; Imberti L; Piantoni S; Frassi M; Tincani A; Airò P
    Clin Exp Rheumatol; 2014; 32(2):204-10. PubMed ID: 24428959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Body mass index and response to abatacept in rheumatoid arthritis.
    Gardette A; Ottaviani S; Sellam J; Berenbaum F; Lioté F; Fautrel B; Palazzo E; Meyer A; Sibilia J; Dieudé P
    Eur J Clin Invest; 2016 Dec; 46(12):1048-1052. PubMed ID: 27736006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline numbers of circulating CD28-negative T cells may predict clinical response to abatacept in patients with rheumatoid arthritis.
    Scarsi M; Ziglioli T; Airo' P
    J Rheumatol; 2011 Oct; 38(10):2105-11. PubMed ID: 21807779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in Predictive Factors for Sustained Clinical Remission with Abatacept Between Younger and Elderly Patients with Biologic-naive Rheumatoid Arthritis: Results from the ABROAD Study.
    Sekiguchi M; Fujii T; Matsui K; Murakami K; Morita S; Ohmura K; Kawahito Y; Nishimoto N; Mimori T; Sano H;
    J Rheumatol; 2016 Nov; 43(11):1974-1983. PubMed ID: 27585689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical, radiographic and functional efficacy of abatacept in routine care for rheumatoid arthritis patients: Abatacept Leading Trial for RA on Imaging Remission (ALTAIR) study.
    Kubo S; Nakano K; Nakayamada S; Hirata S; Fukuyo S; Sawamukai N; Saito K; Tanaka Y
    Clin Exp Rheumatol; 2016; 34(5):834-841. PubMed ID: 27607196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abatacept suppresses the telomerase activity of lymphocytes in patients with rheumatoid arthritis.
    Otani K; Kurosaka D
    Int J Rheum Dis; 2019 Jun; 22(6):1138-1144. PubMed ID: 30938065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longterm efficacy and safety of abatacept in patients with rheumatoid arthritis treated in routine clinical practice: effect of concomitant methotrexate after 24 weeks.
    Takahashi N; Kojima T; Kaneko A; Kida D; Hirano Y; Fujibayashi T; Yabe Y; Takagi H; Oguchi T; Miyake H; Kato T; Watanabe T; Hayashi M; Kanayama Y; Funahashi K; Asai S; Yoshioka Y; Takemoto T; Terabe K; Asai N; Ishiguro N
    J Rheumatol; 2015 May; 42(5):786-93. PubMed ID: 25834204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abatacept therapy reduces CD28+CXCR5+ follicular helper-like T cells in patients with rheumatoid arthritis.
    Fukuyo S; Nakayamada S; Iwata S; Kubo S; Saito K; Tanaka Y
    Clin Exp Rheumatol; 2017; 35(4):562-570. PubMed ID: 28516880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abatacept may be effective and safe in patients with amyloid A amyloidosis secondary to rheumatoid arthritis.
    Nakamura T; Kumon Y; Hirata S; Takaoka H
    Clin Exp Rheumatol; 2014; 32(4):501-8. PubMed ID: 24959698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of abatacept treatment on serum osteoclast-related biomarkers in patients with rheumatoid arthritis (RA): A multicenter RA ultrasound prospective cohort in Japan.
    Kawashiri SY; Endo Y; Nishino A; Okamoto M; Tsuji S; Takatani A; Shimizu T; Sumiyoshi R; Koga T; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Aramaki T; Ueki Y; Yoshitama T; Eiraku N; Matsuoka N; Okada A; Fujikawa K; Hamada H; Nagano S; Tada Y; Kawakami A
    Medicine (Baltimore); 2021 Jul; 100(28):e26592. PubMed ID: 34260539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of abatacept in elderly patients with rheumatoid arthritis enrolled in the French Society of Rheumatology's ORA registry.
    Lahaye C; Soubrier M; Mulliez A; Bardin T; Cantagrel A; Combe B; Dougados M; Flipo RM; Le Loët X; Shaeverbeke T; Ravaud P; Mariette X; Gottenberg JE;
    Rheumatology (Oxford); 2016 May; 55(5):874-82. PubMed ID: 26822072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High Proportion of Subjective Component to the Disease Activity Score is Associated with Favorable Response to Abatacept in Rheumatoid Arthritis.
    Lee JS; Ahmad H; Shim SC; Bae SC; Song YW; Lee EY
    Patient; 2019 Jun; 12(3):319-326. PubMed ID: 30484084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating Th17.1 cells as candidate for the prediction of therapeutic response to abatacept in patients with rheumatoid arthritis: An exploratory research.
    Maeda S; Osaga S; Maeda T; Takeda N; Tamechika SY; Naniwa T; Niimi A
    PLoS One; 2019; 14(11):e0215192. PubMed ID: 31747403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CXCL-13 serum levels in patients with rheumatoid arthritis treated with abatacept.
    Masneri S; Piantoni S; Galoppini G; Regola F; Nalli C; Bazzani C; Franceschini F; Airò P
    Clin Exp Rheumatol; 2022 Nov; 40(11):2103-2108. PubMed ID: 35084306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of Syk in peripheral blood B cells in patients with rheumatoid arthritis: a potential target for abatacept therapy.
    Iwata S; Nakayamada S; Fukuyo S; Kubo S; Yunoue N; Wang SP; Yoshikawa M; Saito K; Tanaka Y
    Arthritis Rheumatol; 2015 Jan; 67(1):63-73. PubMed ID: 25303149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abatacept reduces levels of switched memory B cells, autoantibodies, and immunoglobulins in patients with rheumatoid arthritis.
    Scarsi M; Paolini L; Ricotta D; Pedrini A; Piantoni S; Caimi L; Tincani A; Airò P
    J Rheumatol; 2014 Apr; 41(4):666-72. PubMed ID: 24584924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Etanercept reduces the serum levels of macrophage chemotactic protein-1 in patients with rheumatoid arthritis.
    Kageyama Y; Kobayashi H; Kato N; Shimazu M
    Mod Rheumatol; 2009; 19(4):372-8. PubMed ID: 19458908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.